No. | Lectin | Preferred glycan structure (terminal epitope) | A2780-1 ± SD | CP-1 ± SD | C1/A1 | A2780-2 ± SD | CP-2 ± SD | C2/A2 |
---|---|---|---|---|---|---|---|---|
1 | LTL | Fuc α1-3(Gal β1-4)GlcNAc (Lex), Fuc α1-2(Gal β1-4)GlcNAc | 0.58 ± 0.02 | 0.62 ± 0.01 | 1.07** | 0.47 ± 0.02 | 0.41 ± 0.02 | 0.86* |
2 | PSA | Fuc α1-6GlcNAc, α-D-Glc, α-D-Man | 0.90 ± 0.03 | 1.06 ± 0.02 | 1.17*** | 0.94 ± 0.04 | 1.05 ± 0.07 | 1.11 |
3 | LCAa | Fuc α1-6GlcNAc, α-D-Glc, α-D-Man | 0.86 ± 0.04 | 0.99 ± 0.03 | 1.15*** | 1.02 ± 0.02 | 1.21 ± 0.08 | 1.19** |
4 | UEA-I | Fuc α1-2(Gal β1-4)GlcNAc | 0.43 ± 0.02 | 0.52 ± 0.02 | 1.20*** | 0.48 ± 0.01 | 0.34 ± 0.00 | 0.71*** |
5 | AOLa | Fuc α1-6GlcNAc (core Fuc), Fuc α1-2(Gal β1-4)GlcNAc | 0.49 ± 0.02 | 0.47 ± 0.01 | 0.96*** | 0.52 ± 0.03 | 0.46 ± 0.02 | 0.87* |
6 | AAL | Fuc α1-6GlcNAc (core Fuc), Fuc α1-3(Gal β1-4)GlcNAc (Lex) | 0.80 ± 0.03 | 0.86 ± 0.04 | 1.07*** | 1.04 ± 0.09 | 0.78 ± 0.02 | 0.76* |
7 | MAL | Sia α2-3Gal β1-4GlcNAc | 0.69 ± 0.01 | 0.75 ± 0.01 | 1.10*** | 0.61 ± 0.01 | 0.56 ± 0.01 | 0.91** |
8 | SNAa | Sia α2-6Gal/GalNAc | 1.01 ± 0.07 | 0.83 ± 0.03 | 0.82** | 0.94 ± 0.02 | 0.72 ± 0.04 | 0.77*** |
9 | SSAa | Sia α2-6Gal/GalNAc | 0.95 ± 0.02 | 0.77 ± 0.02 | 0.81*** | 0.94 ± 0.01 | 0.67 ± 0.01 | 0.71*** |
10 | TJA-I | Sia α2-6Gal/GalNAc | 1.98 ± 0.10 | 1.44 ± 0.10 | 0.73*** | 1.16 ± 0.04 | 1.38 ± 0.06 | 1.19*** |
11 | PHA-L | Tri/Tetra-antennary complex-type N-glycan | 0.62 ± 0.02 | 0.69 ± 0.01 | 1.12** | 0.58 ± 0.02 | 0.49 ± 0.01 | 0.85*** |
12 | ECA | Gal β1-4GlcNAc | 1.26 ± 0.04 | 1.22 ± 0.05 | 0.97* | 0.98 ± 0.03 | 0.99 ± 0.05 | 1.01 |
13 | RCA120 | Gal β1-4GlcNAc | 2.36 ± 0.09 | 1.65 ± 0.12 | 0.70*** | 1.97 ± 0.11 | 2.47 ± 0.23 | 1.25*** |
14 | PHA-E | Complex-type N-glycans with outer Gal and bisecting GlcNAc | 1.11 ± 0.02 | 1.15 ± 0.03 | 1.03 | 1.04 ± 0.05 | 1.55 ± 0.05 | 1.50*** |
15 | DSA | (GlcNAc β1-4)n, Gal β1-4GlcNAc, Tri/Tetra-antennary N-glycans | 2.57 ± 0.03 | 2.65 ± 0.09 | 1.03 | 1.58 ± 0.06 | 2.29 ± 0.14 | 1.45*** |
16 | GSL-II | Agalactosylated tri/tetra antennary glycans, GlcNAc | 0.43 ± 0.02 | 0.52 ± 0.02 | 1.20*** | 0.48 ± 0.02 | 0.31 ± 0.01 | 0.66*** |
17 | NPAa | High Man, Man α1-6Man | 1.30 ± 0.02 | 1.47 ± 0.05 | 1.13*** | 1.29 ± 0.08 | 1.85 ± 0.14 | 1.43*** |
18 | ConAa | High Man, Man α1-6(Man α1-3)Man (inhibited by presence of bisecting GlcNAc) | 1.46 ± 0.08 | 2.05 ± 0.03 | 1.40*** | 1.93 ± 0.16 | 2.19 ± 0.15 | 1.13** |
19 | GNAa | High Man, Man α1-3Man | 1.05 ± 0.04 | 1.12 ± 0.05 | 1.07*** | 0.97 ± 0.04 | 1.27 ± 0.11 | 1.30*** |
20 | HHL | High Man, Man α1-3Man, Man α1-6Man | 0.75 ± 0.02 | 0.75 ± 0.02 | 0.99 | 0.82 ± 0.02 | 0.76 ± 0.04 | 0.92* |
21 | ACG | Sia α2-3Gal β1-4GlcNAc | 1.45 ± 0.04 | 1.37 ± 0.07 | 0.94 | 1.55 ± 0.06 | 1.74 ± 0.13 | 1.12** |
22 | TxLC-I | Man3 core, bi- and tri-antennary complex-type N-glycan, GalNAc | 0.64 ± 0.02 | 0.72 ± 0.02 | 1.13** | 0.75 ± 0.02 | 0.68 ± 0.04 | 0.90 |
23 | BPLa | Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc | 0.82 ± 0.02 | 0.60 ± 0.01 | 0.73*** | 0.58 ± 0.01 | 0.52 ± 0.03 | 0.89* |
24 | TJA-IIa | Fuc α1-2Gal β1-4, GalNAcβ1-4 groups at their nonreducing terminals | 1.24 ± 0.03 | 0.89 ± 0.01 | 0.72*** | 1.19 ± 0.06 | 0.78 ± 0.09 | 0.65** |
25 | EEL | Gal α1-3Gal β1-4GlcNAc, Fuc α1-2(Gal α1-3)Galβ1-4GlcNAc | 0.44 ± 0.02 | 0.52 ± 0.02 | 1.17*** | 0.41 ± 0.02 | 0.30 ± 0.02 | 0.72** |
26 | ABA | Gal β1-3GalNAc (α-Thr/Ser (T)), GlcNAc, sialyl-T | 0.86 ± 0.01 | 0.94 ± 0.01 | 1.09*** | 1.01 ± 0.04 | 0.94 ± 0.05 | 0.93* |
27 | LELa | (GlcNAc β1-4)n, (Gal β1-4GlcNAc)n (polyLacNAc) | 3.22 ± 0.28 | 3.65 ± 0.14 | 1.13* | 2.37 ± 0.08 | 3.26 ± 0.18 | 1.37** |
28 | STLa | (GlcNAc)n, (GlcNAc β1-4MurNAc)n (peptidoglycan backbone) | 2.72 ± 0.21 | 2.95 ± 0.22 | 1.09*** | 1.48 ± 0.06 | 2.00 ± 0.13 | 1.35*** |
29 | UDA | GlcNAc β1-4GlcNAc, Mixture of Man5 to Man9 | 1.97 ± 0.22 | 1.65 ± 0.13 | 0.84** | 1.72 ± 0.06 | 1.97 ± 0.18 | 1.14* |
30 | PWMa | (GlcNAc α1-4)n | 0.78 ± 0.08 | 0.52 ± 0.03 | 0.67*** | 0.71 ± 0.03 | 0.39 ± 0.04 | 0.54*** |
31 | Jacalin | Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) | 1.02 ± 0.07 | 1.13 ± 0.08 | 1.11 | 1.50 ± 0.05 | 1.89 ± 0.18 | 1.25** |
32 | PNA | Gal β1-3GalNAc (α-Thr/Ser (T)) | 0.40 ± 0.02 | 0.41 ± 0.03 | 1.02 | 0.62 ± 0.02 | 0.40 ± 0.02 | 0.64*** |
33 | WFAa | Terminal GalNAc (e.g. GalNAcβ1-4GlcNAc), Galβ1-3(-6)GalNAc | 0.94 ± 0.08 | 0.59 ± 0.02 | 0.62*** | 0.79 ± 0.03 | 0.44 ± 0.02 | 0.55*** |
34 | ACA | Gal β1-3GalNAc (α-Thr/Ser (T)) | 0.87 ± 0.06 | 1.21 ± 0.07 | 1.39*** | 1.26 ± 0.05 | 1.25 ± 0.04 | 0.99 |
35 | MPA | Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) | 0.61 ± 0.06 | 0.70 ± 0.06 | 1.15*** | 1.12 ± 0.04 | 0.58 ± 0.03 | 0.52*** |
36 | HPA | α-Linked terminal GalNAc | 0.42 ± 0.04 | 0.56 ± 0.04 | 1.33*** | 0.74 ± 0.02 | 0.51 ± 0.05 | 0.69** |
37 | VVA | α-Linked terminal GalNAc (α-Thr/Ser (Tn), GalNAc α1-3Gal | 0.46 ± 0.01 | 0.45 ± 0.02 | 0.99 | 0.87 ± 0.05 | 0.51 ± 0.02 | 0.58*** |
38 | DBA | GalNAc α1-3GalNAc (Blood group A), GalNAc α1-3GalNAc | 0.40 ± 0.01 | 0.44 ± 0.01 | 1.11*** | 0.61 ± 0.05 | 0.37 ± 0.02 | 0.61*** |
39 | SBAa | α or β-linked terminal GalNAc, GalNAc α1-3Gal | 0.49 ± 0.00 | 0.42 ± 0.02 | 0.85** | 0.80 ± 0.09 | 0.53 ± 0.05 | 0.66*** |
40 | Calsepa | High Man (Man2-6), N-glycans including bisecting GlcNAc | 0.59 ± 0.01 | 0.59 ± 0.00 | 1.01 | 1.15 ± 0.11 | 0.90 ± 0.07 | 0.79** |
41 | PTL-I | α-Linked terminal GalNAc | 0.52 ± 0.01 | 0.51 ± 0.01 | 0.99 | 0.75 ± 0.05 | 0.52 ± 0.04 | 0.70*** |
42 | MAH | Sia α2-3Gal β1-3(Sia α2-6) GalNAc | 0.48 ± 0.01 | 0.52 ± 0.02 | 1.10* | 0.45 ± 0.00 | 0.37 ± 0.02 | 0.83** |
43 | WGA | (GlcNAcβ1-4)n, NeuAc, multivalent Sia | 1.26 ± 0.01 | 1.12 ± 0.04 | 0.89** | 1.26 ± 0.03 | 1.39 ± 0.07 | 1.11* |
44 | GSL-IA4 | α-GalNAc (α-Thr/Ser (Tn)) | 0.39 ± 0.01 | 0.49 ± 0.01 | 1.26*** | 0.69 ± 0.07 | 0.37 ± 0.02 | 0.54** |
45 | GSL-IB4 | α-Gal | 0.39 ± 0.01 | 0.49 ± 0.00 | 1.25*** | 0.87 ± 0.05 | 0.65 ± 0.03 | 0.74*** |